The rights issue, which allows existing investors to buy new shares in the firm at a much lower valuation, was oversubscribed, PharmEasy co-founder Dharmil Sheth said in a LinkedIn post.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback